A Precision high content screening assay for AB-mediated neuronal cell cycle reentry

NIH RePORTER · NIH · R01 · $403,750 · view on reporter.nih.gov ↗

Abstract

Project Summary The death of neurons that control memory and cognition are responsible for the behavioral symptoms of Alzheimer’s disease (AD). One of the most common pathways for neuronal death in AD is cell cycle re-entry (CCR), which represents the reactivation of neuronal cell cycle machinery. Usually, differentiated neurons never attempt to divide, yet up to 5-10% of the neurons in brain regions affected by AD show signs of CCR. These neurons, which typically have duplicated much of their DNA, fail to undergo cytokinesis. Instead, they eventually die and may account for as much as 90% of the neuronal loss seen in AD. This process initiates with exposure to soluble amyloid-β oligomers (AβOs), which are the building blocks of the insoluble amyloid plaques that accumulate in AD brain. Identifying genes and proteins that mediate AβO-mediated neuronal CCR and defining relevant signaling networks hold promise for early AD diagnosis and for developing new AD therapeutics. We have developed a human neural cell model of AβO-mediated neuronal CCR, which utilizes neural iPS cell lines. We intend to use these iPS lines and derived sublines to develop a high content screening (HCS) assay to identify chemotypes that inhibit AβO-mediated CCR. We believe, through this assay, we can identify small molecules that can block AβO-induced neuronal CCR and function as chemical probes to (1) understand the signaling pathways leading to neuronal death by CCR and (2) serve as parental chemotypes for drugs.

Key facts

NIH application ID
10137862
Project number
5R01AG063400-03
Recipient
UNIVERSITY OF VIRGINIA
Principal Investigator
ELIZABETH SHARLOW
Activity code
R01
Funding institute
NIH
Fiscal year
2021
Award amount
$403,750
Award type
5
Project period
2019-04-01 → 2023-01-31